AR032449A1 - Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina - Google Patents
Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolinaInfo
- Publication number
- AR032449A1 AR032449A1 ARP010101263A ARP010101263A AR032449A1 AR 032449 A1 AR032449 A1 AR 032449A1 AR P010101263 A ARP010101263 A AR P010101263A AR P010101263 A ARP010101263 A AR P010101263A AR 032449 A1 AR032449 A1 AR 032449A1
- Authority
- AR
- Argentina
- Prior art keywords
- cabergoline
- cabergolina
- solvato
- procedure
- produce
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 10
- 229960004596 cabergoline Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 102000003946 Prolactin Human genes 0.000 abstract 2
- 108010057464 Prolactin Proteins 0.000 abstract 2
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 2
- 229940097325 prolactin Drugs 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007308.0A GB0007308D0 (en) | 2000-03-24 | 2000-03-24 | Process for preparing crystalline form | of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032449A1 true AR032449A1 (es) | 2003-11-12 |
Family
ID=9888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101263A AR032449A1 (es) | 2000-03-24 | 2001-03-19 | Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6727363B2 (https=) |
| EP (1) | EP1272489B1 (https=) |
| JP (1) | JP4184666B2 (https=) |
| KR (1) | KR100827558B1 (https=) |
| CN (1) | CN1188412C (https=) |
| AR (1) | AR032449A1 (https=) |
| AT (1) | ATE250601T1 (https=) |
| AU (2) | AU780747B2 (https=) |
| BR (1) | BR0109507A (https=) |
| CA (1) | CA2402836A1 (https=) |
| CZ (1) | CZ20023176A3 (https=) |
| DE (1) | DE60100858T2 (https=) |
| DK (1) | DK1272489T3 (https=) |
| EA (1) | EA005928B1 (https=) |
| EE (1) | EE05088B1 (https=) |
| ES (1) | ES2208602T3 (https=) |
| GB (1) | GB0007308D0 (https=) |
| HK (1) | HK1052348B (https=) |
| HU (1) | HUP0300591A3 (https=) |
| IL (2) | IL150985A0 (https=) |
| MX (1) | MXPA02009283A (https=) |
| MY (1) | MY134189A (https=) |
| NO (1) | NO20024321D0 (https=) |
| NZ (1) | NZ521316A (https=) |
| PE (1) | PE20011140A1 (https=) |
| PL (1) | PL358253A1 (https=) |
| PT (1) | PT1272489E (https=) |
| SI (1) | SI1272489T1 (https=) |
| SK (1) | SK13582002A3 (https=) |
| WO (1) | WO2001070740A1 (https=) |
| ZA (1) | ZA200206045B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| IL163779A0 (en) * | 2002-03-15 | 2005-12-18 | Pharmacia Corp | Process for preparing crystalline form i of cabergoline |
| PL374503A1 (en) * | 2002-03-15 | 2005-10-31 | Pharmacia Corporation | Process for preparing crystalline form i of cabergoline |
| IL155545A (en) | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| KR20060028761A (ko) | 2003-05-08 | 2006-04-03 | 아이박스 파마슈티컬스 에스.알.오. | 다형의 카베르골린 |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| GB0515430D0 (en) * | 2005-07-27 | 2005-08-31 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| US8637099B2 (en) * | 2007-08-29 | 2014-01-28 | Max Zeller Sohne Ag | Use of Vitex agnus castus extracts for preparing a medicament |
| EP4074552B1 (en) * | 2021-04-16 | 2024-04-03 | Thermo King LLC | Electrical connection unit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3019322A1 (de) | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB9205439D0 (en) * | 1992-03-12 | 1992-04-22 | Erba Carlo Spa | Process for the synthesis of ergoline derivatives |
| WO1995005176A1 (en) | 1993-08-18 | 1995-02-23 | Alcon Laboratories, Inc. | Use of ergoline derivatives for the treatment of glaucoma |
| JP2002509119A (ja) | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物 |
| JP2002507562A (ja) | 1998-03-27 | 2002-03-12 | ファルマシア・アンド・アップジョン・カンパニー | レストレスレッグ症候群の治療におけるカベルゴリンの使用 |
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
-
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
-
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321D0/no not_active Application Discontinuation
-
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032449A1 (es) | Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| CN203777119U (zh) | 跟腱延长术后康复支具 | |
| DE60044152D1 (de) | Bupropion Metaboliten zur Behandlung von Angstzuständen | |
| GT200100147A (es) | Derivados de imidazol | |
| DOP2003000566A (es) | Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento | |
| AR041932A1 (es) | Derivados de ciclohexano espirociclicos, preparacion de los mismos, su uso en la fabricacion de medicamentos y dichos medicamentos. | |
| ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
| GT200400098A (es) | Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas. | |
| IL186200A (en) | Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness | |
| ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
| MXPA04004552A (es) | Compuestos tipo indolizina sustituida y metodos de uso. | |
| Sangkaew | Distraction osteogenesis for the treatment of post traumatic complications using a conventional external fixator: a novel technique | |
| JO2505B1 (en) | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels | |
| IL172419A0 (en) | Piperazine derivatives and methods of use | |
| CO5370677A1 (es) | Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina | |
| MXPA03006943A (es) | Derivados de carbonilo sustituidos heterocicliclos y su uso como ligandos para el receptor d3 de la dopamina. | |
| EA200300266A1 (ru) | Новые сложные эфиры апорфина и их применение в терапии | |
| BR0115708A (pt) | Compostos derivados de benzotiofeno, seu processo de obten-ção e uso dos mesmos | |
| WO2010011836A3 (en) | Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof | |
| NZ790364A (en) | Compounds and compositions for use in treating skin disorders | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| PA8519401A1 (es) | Derivados de 3-azabiciclo(3.1.0)hexano utiles en terapia | |
| SE9803760D0 (sv) | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel | |
| PE20011087A1 (es) | Forma ii cristalina de cabergolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |